Furazolidone - CAS 67-45-8
Catalog number:
67-45-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C8H7N5O3
Molecular Weight:
225.16
COA:
Inquire
Targets:
Antibacterial
Description:
Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity, binds bacterial DNA, which leads to the gradual inhibition of monoamine oxidase used to treat anorexia and antagonism of thiamin utilization in poultry (IC50=12.7 μM).
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
Yellow Solid
Synonyms:
3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone;3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; Topazone;Trifurox
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Antimicrobial.
Quality Standard:
Enterprise Standard/EP
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Grams-Kilos
Melting Point:
247-249°C
InChIKey:
PLHJDBGFXBMTGZ-WEVVVXLNSA-N
InChI:
1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
Canonical SMILES:
C1COC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-]
1.Formulation and advantages of furazolidone in liposomal drug delivery systems.
Alam MI1, Paget T1, Elkordy AA2. Eur J Pharm Sci. 2016 Mar 10;84:139-45. doi: 10.1016/j.ejps.2016.01.017. Epub 2016 Jan 18.
Furazolidone has proven to have antiprotozoal and antibacterial activity. A number of literature supported its use against Helicobacter pylori. This potential application opens new prospects of its use in clinical settings in triple therapy. In order to avoid side effects associated with this drug, liposomal mucoadhesive drug delivery that can work locally in stomach is considered as an appropriate approach. This study is a focus on formulations and in vitro characterization of liposomes containing furazolidone. Therefore, the effects of variable amounts of drug and cholesterol on encapsulation efficacy and in vitro drug release were evaluated for different liposomal formulations. Mucoadhesive behavior of chitosan coated liposomal at two different pHs was also evaluated and increase in pH from 1.3 to 4.5 increased mucoadhesion from 42% to 60% respectively. Increasing the amount of drug from 4mg to 5mg increased encapsulation activity however, increasing the drug any further decreased encapsulation activity.
2.Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure.
Fakheri H1, Bakhshi Z2, Bari Z3, Alhooei S3. Middle East J Dig Dis. 2016 Jan;8(1):51-6. doi: 10.15171/mejdd.2016.07.
BACKGROUND Several large clinical trials and meta-analyses have shown about 20% failure to eradicate Helicobacter pylori (H.pylori), necessitating investigations for second-line treatments. The aim of this study was to evaluate the effects of clarithromycin-containing quadruple regimen after nitroimidazole-containing quadruple therapy failure. METHODS Thirty two patients who had failed 10-day H.pylori treatment with omeprazole, amoxicillin, bismuth subcitrate, and metronidazole (OABM) regimen and 31 patients who had failed 10-day treatment with omeprazole, amoxicillin, bismuth subcitrate, and furazolidone (OAMF) regimen entered the study. They all received omeprazole (20 mg), amoxicillin (1 gr), bismuth subcitrate (240 mg) and clarithromycin (500 mg) twice a day for 10 days. Eight weeks after treatment, H. pylori eradication was assessed by (14)C-urea breath test. RESULTS Totally 61 patients completed the study. According to intention to treat (ITT) analysis, eradication rates by second-line OABC regimen were 84.
3.Efficacy of a quadruple therapy regimen for Helicobacter pylori eradication after partial gastrectomy.
Zhang F1, Bao ZJ1, Shi DM1, Xiang P1, Xiao L1, Huang YQ1, Zhang GS1, Yin SM1. Braz J Med Biol Res. 2016 Feb;49(2):e5080. doi: 10.1590/1414-431X20155080. Epub 2016 Feb 5.
We aimed to evaluate the effectiveness and safety of bismuth-containing quadruple therapy plus postural change after dosing for Helicobacter pylori eradication in gastrectomized patients. We compared 76 gastric stump patients with H. pylori infection (GS group) with 50 non-gastrectomized H. pylori-positive patients who met the treatment indication (controls). The GS group was divided into GS group 1 and GS group 2. All groups were administered bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days. GS group 1 maintained a left lateral horizontal position for 30 min after dosing. H. pylori was detected using rapid urease testing and histologic examination of gastric mucosa before and 3 months after therapy. Mucosal histologic manifestations were evaluated using visual analog scales of the updated Sydney System. GS group 1 had a higher prevalence of eradication than the GS group 2 (intention-to-treat [ITT]: P=0.
4.[Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province].
Meng X1, Liu GF, Wu J, Kong CC, Zhao LW, Zhu XY, Ji CG, Yang L. Zhonghua Yi Xue Za Zhi. 2016 Jan 26;96(4):270-2. doi: 10.3760/cma.j.issn.0376-2491.2016.04.008.
OBJECTIVE: To evaluate the resistance of Helicobacter pylori (H.pylori) clinical isolates to various antibiotics, in order to guide rational drug use in Hebei Province.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 14222-60-7 Prothionamide

Prothionamide
(CAS: 14222-60-7)

An anti-tuberculosis agent. It has also been used to treat Leprosy. Antibacterial (tuberculostatic).

CAS 220620-09-7 Tigecycline

Tigecycline
(CAS: 220620-09-7)

A glycylcycline antibiotic, used to treat infection by drug resistant bacteria such as Staphylococcus aureus (Staph aureus) and Acinetobacter baumannii.

CAS 197654-04-9 Tigecycline hydrochloride

Tigecycline hydrochloride
(CAS: 197654-04-9)

Tigecycline is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial a...

CAS 138-39-6 Mafenide

Mafenide
(CAS: 138-39-6)

Mafenide is a sulfonamide-type medication.

CAS 54-85-3 Isoniazid

Isoniazid
(CAS: 54-85-3)

Isoniazid is a prodrug and must be activated by bacterial catalase.

Lascufloxacin
(CAS: 848416-07-9)

Lascufloxacin is an antibacterial drug candidate. Phase-III clinical trials in Respiratory tract infections and in Community-acquired pneumonia in Japan were on...

CAS 171500-79-1 Dalbavancin

Dalbavancin
(CAS: 171500-79-1)

Dalbavancin is a semi-synthetic glycopeptide by introducing a positively charged lipophilic moiety in a previously unexplored region of the natural glycopeptide...

CAS 1025097-10-2 Cadazolid

Cadazolid
(CAS: 1025097-10-2)

Cadazolid, also referred to ACT-179811,is a new fluoroquinolone-oxazolidinone antibiotic with potent activity against Clostridium difficile.

CAS 32986-56-4 Tobramycin

Tobramycin
(CAS: 32986-56-4)

Tobramycin is an aminoglycoside antibiotic with an IC50 of 9.7 μM.

CAS 91296-87-6 Sarafloxacin HCl

Sarafloxacin HCl
(CAS: 91296-87-6)

Sarafloxacin is a quinolone antibiotic drug, inhibiting the topoisomerase II ligase domain.

CAS 84294-96-2 Enoxacin hydrate

Enoxacin hydrate
(CAS: 84294-96-2)

Enoxacin hydrate is a synthetic antibiotic belonging to quinolone carboxylic acid compound. It is bactericidal and has a postantibiotischen effect. It is a broa...

CAS 111696-23-2 Cefetamet Pivoxil Hydrochloride

Cefetamet Pivoxil Hydrochloride
(CAS: 111696-23-2)

The hydrochloride salt form of Cefetamet pivoxil, one of the third generation cephalosporin antibiotics, could be effective in the treatment for sorts of infect...

CAS 878419-78-4 Walrycin B

Walrycin B
(CAS: 878419-78-4)

Walrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator. It is known as an analog of toxoflavin, which has bee...

CP 99433
(CAS: 147059-71-0)

CP 99433, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor that could be probably effective as an antibacterial agent.

CAS 1405-53-4 Tylosin phosphate

Tylosin phosphate
(CAS: 1405-53-4)

Tylosin phosphate(Fradizine; Tylocine; Tylosin A) is a broad spectrum antibiotic against Gram-positive organisms and a limited range of Gram-negative organisms.

CAS 331963-29-2 I2906

I2906
(CAS: 331963-29-2)

Under in vitro conditions, I2906 showed excellent antimycobacterial activities and low cytotoxicity. In a murine model infected with M. tuberculosis H37Rv, the ...

CAS 80-08-0 Dapsone

Dapsone
(CAS: 80-08-0)

Dapsone is a sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae, which has anti-inflammatory and i...

CAS 64485-93-4 Cefotaxime Sodium

Cefotaxime Sodium
(CAS: 64485-93-4)

Cefotaxime Sodium, a third-generation cephalosporin antibiotic, has broad spectrum activity against Gram positive and Gram negative bacteria.

CAS 773-76-2 Chloroxine

Chloroxine
(CAS: 773-76-2)

Chloroxine has bacteriostatic, fungistatic and antiprotozoal properties. It is effective against Streptococci, Staphylococci, Candida, Candida albicans, Shigell...

CAS 1257426-19-9 TBA-354

TBA-354
(CAS: 1257426-19-9)

TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamani...

Chemical Structure

CAS 67-45-8 Furazolidone

Quick Inquiry

Verification code

Featured Items